Cases
South Korean biotech firm establishes its first European entity in Copenhagen
Mar 5, 2026 South Korean biotech ORGANOPlus embeds its platform, which reduces animal testing, within Medicon Valley’s strong ecosystem. The company is opening its first European entity in Copenhagen with assistance from Copenhagen Capacity.South Korea–based biotech company ORGANOPlus initiates its European presence with assistance from Copenhagen Capacity. ORGANOPlus has developed a next-generation multi-organ organoid-on-chip (MOOC) validation platform that can reduce animal testing and accelerate safe pharma production by focusing on reducing late-stage clinical failure risk and generating measurable, human-derived biological data.
By establishing its first European entity in Copenhagen, ORGANOPlus embeds its validation platform within Greater Copenhagen’s life science ecosystem, Medicon Valley - home to about 350 biotech and pharmaceutical companies and a large concentration of life science professionals.
“Copenhagen offers one of the most advanced life science ecosystems in the world. Our goal is to scale our human-based predictive validation platform and contribute to establishing a European standard for human-relevant preclinical validation,” says Jaeyoung Shin, CEO of ORGANOPlus.
ORGANOPlus’ new Copenhagen entity will focus on EU partnership development, microbiome-based live biotherapeutic validation, oncology-related translational modelling, and the generation of regulatory-grade validation datasets.
Introduced to a leading life science ecosystem by Copenhagen Capacity
By now anchoring its European activities in Copenhagen, ORGANOPlus contributes to strengthening Medicon Valley’s strongholds in immunology, microbiome research, oncology, and translational medicine, providing a solid foundation for advancing human-relevant validation technologies.
“ORGANOPlus’s decision to establish its European entity in Copenhagen reflects the strength of Medicon Valley’s life science ecosystem and leading position in next-generation preclinical innovation,” says Asbjørn Overgaard, CEO at Copenhagen Capacity.
Copenhagen Capacity has assisted ORGANOPlus with tailored guidance on regulatory alignment, ecosystem integration, and local partnership development. This structured support is expected to enable efficient soft landing and accelerate strategic collaboration within the Danish and European life science network.
In photo: Niels Christian Ganderup (Copenhagen Capacity), Jaeyoung Shin (CEO, Organoplus), Sungsu Park (CSO, Organoplus), Niels Thun Andersen (Copenhagen Capacity)
Are you also considering expanding to Greater Copenhagen?
At Copenhagen Capacity, we assist startups and established companies expanding to and in Greater Copenhagen. Whether it's setting up a Sales Office, R&D centre, or Regional headquarters - we provide guidance throughout the entire process.
Our services are free for foreign-owned companies and tailored to your business needs, with full confidentiality. We look forward to hearing from you.